Ling Tu

Dr. Ling Tu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Pharmacological Research
Verified
Journal Article
Closed access
LLLiman Luo
Liman Luo
JLJinlan Luo
Jinlan Luo
YCYueting Cai
Yueting Cai
MFMenglu Fu
Menglu Fu
WLWenhua Li
Wenhua Li
YYYan Yang
Yan Yang

1 July 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ZCZhihui Chen
Zhihui Chen
JYJing Yu
Jing Yu
MFMenglu Fu
Menglu Fu
RDRuolan Dong
Ruolan Dong
YYYan Yang
Yan Yang
LTLing Tu
Ling Tu

7 October 2020 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
LLLiman Luo
Liman Luo
MFMenglu Fu
Menglu Fu
YLYuanyuan Li
Yuanyuan Li
SHShuiqing Hu
Shuiqing Hu
JLJinlan Luo
Jinlan Luo
XXXizhen Xu
Xizhen Xu
Backgroud: The association between underlying comorbidities and cardiac injury and the prognosis in coronavirus disease 2019 (COVID‐19) patients was assessed in this study.Hypothesis: The underlying comorbidities and cardiac injury may be associated with the prognosis in COVID‐19 patients.Methods: A systematic search was conducted in PubMed, EMBASE, Web of science, and The Cochrane library from December 2019 to July 2020. The odds ratio (OR) and 95% confidence intervals (95% CI) were used to estimate the probability of comorbidities and cardiac injury in COVID‐19 patients with or without severe type, or in survivors vs nonsurvivors of COVID‐19 patients.Results: A total of 124 studies were included in this analysis. A higher risk for severity was observed in COVID‐19 patients with comorbidities. The pooled result in patients with hypertension (OR 2.57, 95% CI: 2.12‐3.11), diabetes (OR 2.54, 95% CI: 1.89‐3.41), cardiovascular diseases (OR 3.86, 95% CI: 2.70‐5.52), chronic obstractive pulmonary disease (OR 2.71, 95% CI: 1.98‐3.70), chronic kidney disease (OR 2.20, 95% CI: 1.27‐3.80), and cancer (OR 2.42, 95% CI: 1.81‐3.22) respectively. All the comorbidities presented a higher risk of mortality. Moreover, the prevalence of acute cardiac injury is higher in severe group than in nonsevere group, and acute cardiac injury is associated with an increased risk for in‐hospital mortality.Conclusion: Comorbidities and acute cardiac injury are closely associated with poor prognosis in COVID‐19 patients. It is necessary to continuously monitor related clinical indicators of organs injury and concern comorbidities in COVID‐19 patients.

1 June 2020 in Shock
Verified
Journal Article
Open access
ZCZhihui Chen
Zhihui Chen
YTYing Tang
Ying Tang
JYJing Yu
Jing Yu
RDRuolan Dong
Ruolan Dong
YYYan Yang
Yan Yang
XXXizhen Xu
Xizhen Xu
Background: Sepsis is a life-threatening organ dysfunction initiated by a dysregulated response to infection, with imbalanced inflammation and immune homeostasis. Macrophages play a pivotal role in sepsis. N-[1-(1-oxopropyl)-4-piperidinyl]-N’-[4-(trifluoromethoxy)phenyl)-urea (TPPU) is an inhibitor of soluble epoxide hydrolase (sEH), which can rapidly hydrolyze epoxyeicosatrienoic acids (EETs) to the bio-inactive dihydroxyeicosatrienoic acids. TPPU was linked with the regulation of macrophages and inflammation. Here, we hypothesized that sEH inhibitor TPPU ameliorates cecal ligation and puncture (CLP)-induced sepsis by regulating macrophage functions. Methods: A polymicrobial sepsis model induced by CLP was used in our study. C57BL/6 mice were divided into four groups: sham+ phosphate buffer saline (PBS), sham+TPPU, CLP+PBS, CLP+TPPU. Mice were observed 48 h after surgery to assess the survival rate. For other histological examinations, mice were sacrificed 6 h after surgery. Macrophage cell line RAW264.7 was used for in vitro studies. Results: TPPU treatment, accompanied with increased EETs levels, markedly improved the survival of septic mice induced by CLP surgery, which was associated with alleviated organ damage and dysfunction triggered by systemic inflammatory response. Moreover, TPPU treatment significantly inhibited systemic inflammatory response via EETs-induced inactivation of mitogen-activated protein kinase signaling due to enhanced macrophage phagocytic ability and subsequently reduced bacterial proliferation and dissemination, and decreased inflammatory factors release. Conclusion: sEH inhibitor TPPU ameliorates cecal ligation and puncture-induced sepsis by regulating macrophage functions, including improved phagocytosis and reduced inflammatory response. Our data indicate that sEH inhibition has potential therapeutic effects on polymicrobial-induced sepsis.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JLJinlan Luo
Jinlan Luo
SHShuiqing Hu
Shuiqing Hu
MFMenglu Fu
Menglu Fu
LLLiman Luo
Liman Luo
YLYuanyuan Li
Yuanyuan Li
XXXizhen Xu
Xizhen Xu
The epoxyeicosatrienoic acid (EET) exerts beneficial effects on insulin resistance and/or hypertension. EETs could be readily converted to less biological active diols by soluble epoxide hydrolase (sEH). However, whether sEH inhibition can ameliorate the comorbidities of insulin resistance and hypertension, and the underlying mechanisms of this relationship, are unclear. In this study, C57BL/6 mice were rendered hypertensive and insulin resistant through a high-fat and high-salt (HF-HS) diet. The sEH inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) was used to treat mice (1 mg/kg/d) for 8 weeks, followed by analysis of metabolic parameters. The expression of sEH and the sodium-glucose cotransporter 2 (SGLT2) were markedly upregulated in the kidneys of mice fed a HF-HS diet. We found that TPPU administration increased kidney EET levels, improved insulin resistance, and reduced hypertension. Furthermore, TPPU treatment prevented upregulation of SGLT2, and the associated increased urine volume and the excretion of urine glucose and urine sodium. Importantly, TPPU alleviated renal inflammation. In vitro, human renal proximal tubule epithelial cells (HK-2 cells) were used to further investigate the underlying mechanism. We observed that 14,15-EET or sEH knock-down or inhibition prevented the upregulation of SGLT2 upon treatment with palmitic acid or NaCl by inhibiting the IKKα/β/NF-κB signaling pathway. In conclusion, sEH inhibition by TPPU alleviated insulin resistance and hypertension induced by a HF-HS diet in mice. The increased urine excretion of glucose and sodium was mediated by decreased renal SGLT2 expression due to inactivation of the IKKα/β/NF-κB-induced inflammatory response.

1 March 2021 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MFMenglu Fu
Menglu Fu
JYJing Yu
Jing Yu
ZCZhihui Chen
Zhihui Chen
YTYing Tang
Ying Tang
RDRuolan Dong
Ruolan Dong
XXXizhen Xu
Xizhen Xu